Tharimmune Inc THAR

NAS: THAR | ISIN: US4327051011   1/04/2026
3,240 USD (-0,92%)
(-0,92%)   1/04/2026

17 februari 2026 · Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy · Persbericht

6 februari 2026 · Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer · Persbericht

2 februari 2026 · Tharimmune Elects Jill Sommers and William Wiley to Board of Directors · Persbericht

26 januari 2026 · Tharimmune Announces Expanded Role as Super Validator on Canton Network · Persbericht

22 januari 2026 · Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering · Persbericht

20 januari 2026 · Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering · Persbericht

18 december 2025 · Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network · Persbericht

13 november 2025 · Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids · Persbericht

6 november 2025 · Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy · Persbericht

3 november 2025 · Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy · Persbericht

8 november 2023 · Thinking about buying stock in PaxMedica, Applied Therapeutics, Tharimmune, Singular Genomics Systems, or BIOLASE? · Persbericht

Mijn selecties